Matthias Wirth, Siavosh Mahboobi, Oliver H. Krämer, Günter Schneider. (12-09-2016).

PDF

Department: 

Research Area C

Abstract: 

Current data suggest that MYC is an important signaling hub and driver in pancreatic ductal adenocarcinoma (PDAC), a tumor entity with a strikingly poor prognosis. No targeted therapies with a meaningful clinical impact were successfully developed against PDAC so far. This points to the need to establish novel concepts targeting the relevant drivers of PDAC, like KRAS or MYC. Here, we discuss recent developments of direct or indirect MYCinhibitors and their potential mode of action in PDAC.